The incidence of cancer patients with the TP53 pathogenic variant has been reported by two large-scale studies on pediatric cancers [25, 26], and four clinical sequence studies on cancer [27–30]; both of which indicated that the incidence is about 2%. Here, TP53 is linked to cancer.